Fetal Abnormalities of Viral Origin*
PAUL D. PARKMAN, M.D. AND HARRY M. MEYER, JR., M.D.
Laboratory of Viral Immunology, Division of Biologics Standards,
National Institutes of Health, Bethesda, Maryland

The high incidence of acute infections known
to occur in pregnant women contrasts with the
relative rarity of fetal damage and attests to
the efficiency of the mechanisms by which the
fetus is protected in utero.
The events shown in Fig. 1 summarize some
of the obstacles which a virus must overcome in
order to reach the fetus and produce defects. An
effective exposure is required to allow the virus
to multiply locally in the maternal tissues at the
portal of entry. If a viremic phase results the ,.Virus
becomes disseminated and the placent~ riia:Y' be
infected; depending on the type of infottion,
placental damage may or may not result. If the virus
successfully crosses the placental barrier, the fetus
may become infected either by way of fetal viremia
or by contiguous spread through the membranes.
Since maternal viremia is necessary to initiate this
chain of events, the fetus is naturally protected
against vin1ses which seldom invade the blood
stream. Most of the viruses causing respiratory
diseases fall into this category. The maternal immunologic system provides significant protection
by circulating antibodies stimulated by earlier natural or vaccine induced infection. Even if the mother
is susceptible and the infection is associated with
viremia, the virus may still be effectively stopped
by the placental barrier; this has been shown to
occur commonly in both rubella and cytomegalovirus (CMV) infection. If, on the other hand, the
virus reaches the fetus, to produce a teratogenic
effect the virus must have a delicately controlled
pathogenicity allowing a chronic infection to be
established compatible with a period of continued
growth and development. Only two or perhaps
three human viruses have been documented to
have the ability to produce such infections. These
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Fig. I-Events leading to fetal infection and disease.

include rubella virus, human cytomegalovirus, and,
possibly, herpesvirus hominis (herpes simplex virus).
Of these three hutrian viruses, the teratogenic
effeCts of herpes simplex virus are the least
documented. There are 5 reports in the literature
suggesting that genital herpes infections acquired
early in pregnancy may be associated with congenital malformations. Defects seen in these .5 infants
included microcephaly, microphthalmus, and char~
ioretinitis. Skin lesions were present either at
birth or soon thereafter in 3 cases arid encephalitis was present in 1 instance. Investigation of the
infants with microcephaly for other possible infectious etiologies includirig cytomegalovirus and
toxoplasmosis infection gave negative results. The
association of herpes simplex virus with eye and
central nervous system (CNS) defects in these cases
is highly suggestive that this virus may on occasion
be teratogenic; the role of herpes simplex virus in
this regard deserves further investigation (Nahmias,
et al, 1970).
As the result of a decade of intensive interest,
rubella represents the most adequately studied
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congenital infection producing fetal defects (Krugman, 1969). It also represents the only teratogenic
virus infection currently controllable through the
use of vaccine.
Rubella is recognized to occur every year in
sporadic outbreaks covering restricted areas. Since
1928 major epidemics of the di~ease involving the
entire country or large sections of the country have
occurred at 6- to 9-year intervals. Rubella shows
the same prominent seasonal pattern of other diseases transmitted by the · respiratory route. The
maximum incidence of the disease occurs during the
winter and spring months, with very low rates in
summer and fall. In a nonepidemic year, it has
been estimated that the occurrence of rubella in
pregnant women is in excess of 8/10,000 pregnancies. In an epidemic year, this rate may increase
30 to 40 times.
·
The clinical features of natural rubella virus
infection vary from the clinically inapparent to
an illness of sufficient severity to be confused
with measles. Children before the age of puberty
tend to have a mild illness consisting typically
of 3 days of low-grade fever, seldom exceeding
101 °F, rash, and generalized lymphadenopathy.
Nodes are especially prominent in the posterior
cervical region. In adults, particularly women,
the illness is often more severe. The earliest evidence of infection is lymphadenopathy. The nodes
may be tender and the enlargement often persists
for several weeks after the onset of symptoms.
The rash is variable in appearance. Ordinarily,
it first becomes apparent on the face and spreads
rapidly to the trunk and upper extremities. It may
have begun to fade on the face by the time it becomes fully developed on the lower extremities.
Prominent respiratory tract symptoms do not occur.
Women with . rubella sometimes also complain
of headache, malaise, myalgia, painful gums, and
paresthesias, particularly of the hands.
Rubella is the only viral infection in this
country which is frequently associated with arthralgia and arthritis. Age and sex have a marked effect
on the frequency and severity of these symptoms.
In a recent retrospective survey following an
epidemic, 25 % of prepubertal children ~xperienced
joint-related symptoms. After puberty there was a
sharp increase in the . incidence of arthralgia and
arthritis, and with increasing age between menarche
and menopause the frequency and severity of involvement increased progressively. Commonly the
joint symptoms followed the rash by several days,
although in some instances arthritis preceded the

25

rash . or was delayed until several weeks after the
onset "'of 'infection. The joints involved, in order of
frequency, were the proximal interphalangeal
joints, the knees, wrists, ankles, and the metatarsophalangeal joints. Symptoms ordinarily subsided in 1 to 14 days but some patients, notably
older women, experienced recurring symptoms
lasting for a year or more. Even in such instances
symptoms have cleared and there has been no
residual deformity. There is no evidence that these
reactions predispose to the development of chronic
arthritis.
· ·In the typical case, virus may be recovered
from blood and respiratory secretions one to one
and a half weeks prior to the onset of rash.
Viremia disappears shortly after the onset of rash
in association with the appearance of circulating
antibodies. Presence of virus in the respiratory
tract diminishes more slowly; virus may continue to
be recoverable for several weeks. Neutralizing
and hemagglutination-inhibiting (HAI) antibodies
develop promptly after the exanthem appears and
persist for years, probably for life. The CF
antibody response is slightly delayed and may
decline over · a period of years. The widespread
availability of the HAI test has made the rubella
serodiagnosis of critical cases available to everyone. Establishing an accurate diagnosis is nowhere
more important than in the instance when a pregnant woman is exposed to rubella. Under such
circumstances, an initial serum specimen should
be obtained as soon as possible after exposure and
tested for antibodies to determine the immune
status of the patient. Subsequent sa.mples should
be collected in early convalescence · if disease
develops and in asymptomatic patients at 4 and
6 weeks after exposure. These later samples tested
in parallel with the earlier ·specimen will document
if infection has occurred.
In 1940, a communication appeared in a prominent medical journal protesting interest in rubella
as inappropriate since it was "an entirely inconsequential disea.se." This misconception was laid to
rest within the next year by the astute observations
of an Australian ophthalmologist. This was the contribution of the late Sir Norman Gregg, who opened
the field of viral teratogenesis as a result of his
discovery of the association between maternal
rubella, congenital cataract, and heart defects.
Over the years since Gregg's original observations,
it has become apparent that virtually any organ
system of the developing fetus may be damaged.
The fetal infection may be severe enough to
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cause spontaneous abortion or stillbirth. Congenital
involvement often present in the newborn period
included deafness, heart disease, retardation, meningoencephalitis, microcephaly, eye defects, including congenital cataract, retinopathy and glaucoma, purpura, anemia, hepatosplenomegaly with
hepatitis an~ jaundice, pneumonitis, · and bone
lesions.
The earlier in pregnancy maternal rubella
occurred, the more likely jt was that the defects
would be multiple and severe. Follow-up data
indicated that infectjon. during the nrst 2 months of
gestation was associated wjth the highest incidence
of heart, eye, and CNS defects; fetuses infected in
the 3rd month had significantly fewer heart and eye
defects. All types of malformations declined in
those babies who had been infected during the
4th month (Cooper, et al, 1969). It ha~ been estimated that the chances of anomalies when maternal infection occurs during the first month is in
excess of 50%, in the second month about 22%,
and in the 3rd through 5th months, 6% to 10%.
In the pathogenesis of congenital rubella,
viral invasion of the placenta occurs during the
peri9d of materna·l viremia. Replication of virus
in the placenta produces focal areas of mild inflammatory response and scattered damage of the
endothelium of the chorionic blood vessels. Extension of the infection to the fetal circulation permits the virus to reach the developing organs
where a persistent infection ensues. This infection
may be localized or widely disseminated throughout
the fetal tissues. Virus shedding in pharyngeal secretions and urine and the presence of virus in the
tissues can be demonstrated throughout the neonatal period; in those infants with severe rubella
defects, particularly, virus shedding may continue
sporadically int~ the second year. The presistence
of virus is of epidemiological importance since
rubella infected infants can transmit their infectiOn
to nursery personnel and other contacts; thus · it
is important to limit the contact of such infants
with pregnant women in the hospital and after
discharge;
·
Antibody responses in maternal rubella, as
with most infectious diseases, consist of the early
appearance of transient IgM antibody, promptly
followed and eventually replaced by the IgG class
of antibodies. It is the latter which are responsible
for the long-term persisting rubella antibodies.
The situation in the infected fetus is more complex.
Maternal IgG is transplacentally transferred. The
infected fetus begins to produce his own immune

substances, in the form of IgM antibodies, at some
period during the second trimester. At birth the
titer of antibodies in maternal and infant sera is
very nearly the same. The infant's antibodies are
made up of both transplacental IgG and endogeneous IgM. As many as 80% of rubella infants will
have an ·elevated IgM serum protein fraction during the neonatal period. During the first year of
life, passively acquired IgG declines. The production of infant IgG appears during the early
months of life, and late in the first year replaces
IgM as the predominant rubella antibody.
· At · the present time, short of therapeutic
abortion, there are two methods for averting
congenital rubella : ( 1) passive immunization of
exposed pregnant women using commercially
available immune serum globulin (gamma globulin); and (2) the use of live attenuated rubella
vifus vaccine for active immunization of nonpregnant subjects.
Gamma globulin has been commonly used
for many years for the prevention of rubella infection in exposed pregnant women. The efficacy
ofthis procedure has been a matter of controversy.
There is no question that large doses of globulin
given prior to exposure are effective in decreasing
the incidence of infection and the clinical manifestations among those who acquire infection. In
tfle ordinary circumstance in which globulin is
used, however, exposure has already occurred
several days earlier. In such cases the beneficial
effect of globulin · is less well documented. In fact,
~hildren with rubella syndrome defects have been
born to mothers given appropriately timed adequate doses of gamma globulin. Carefully performed
virologic studies, designed to mimic the usual postexposure situation encountered clinically, failed to
show protection against experimental infections,
although there was some effect in diminishing the
duration of viremia. From these data, it is obvious
that globulin is unreliable as a measure for the
prevention of congenital defects. On the other hand,
it is impossible to be certain that globulin, through
reducing the duration or level of viremia, might
not have some effect in reducing the risk of fetal
infection. On this basis, and because it represents
the only currently available measure which might be
of help in this situation, our feeling is that the
continued use of large doses (20 ml of gamma
globulin) is justifiable in circumstances where interruption of pregnancy is not desired.
Live rubella vaccines are prepared in cell cultures and induce immunity by producing a modi-
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fied rubella infection in susceptible persons (Meyer
and Parkman, 1971). The 3 vaccines currently
available are produced in duck embryo cells by
Merck, Sharp, and Dohme (Meruvax®), in canine
renal cells by Philips Roxane, Inc. (marketed by
them as rubella virus vaccine, live) and by Parke
Davis and Co. as Rubelogen®, and in rabbit renal
cells by Smith Kline and French, Inc. (Cendevax®).
In children, vaccine induced infections are usually
asymptomatic, while adults may develop rubella
like symptoms. Such symptoms may consist of
an evanescent rash, lymphadenopathy, and transient peripheral nerve and joint involvement. The
most troublesome complaints have been related
to occurrence of arthralgias, arthritis, and paresthesias; these symptoms follow a pattern of distribution similar to that seen in the natural
disease. They appear within 3 to 5 weeks after
immunization, but on occasion may be delayed until
8 weeks postvaccination. Reaction rates in women
of childbearing age range from 10% to 60% and
as in the natural disease are in part related to the
age of the woman; reaction rates have been highest
in the older age groups. The immunogenicity of the
vaccine used also affects the likelihood of reactions. The canine renal cell prepared vaccine which
produces higher antibody levels was also responsible
for higher reaction rates than vaccines prepared in
duck or rabbit cells. The joint manifestations are
usually mild; however, occasionally a patient may
continue to have residual subjective complaints lasting for weeks or months. Persons with arthritic
manifestations have not shown the development
of later chronic joint disease.
Rubella vaccines stimulate antibodies in 95 %
to 100% of recipients between the 2nd and 4th
weeks postvaccination. Thus far, these antibodies
have been shown to persist without significant
decline throughout the 5-year period of observation since the earliest vaccinations were performed.
In the United States, efforts of mass vaccination programs have been directed toward the immunization of children. This approach is designed
to reduce the opportunities for spread of virus
by decreasing the susceptible childhood population most responsible for initiating and maintaining
epidemic rubella. At the same time, the desirability
of providing protection for the susceptible adult
women is also recognized. Immunization of this
group presents special problems. Arthritic reactions are more common in this age range; most important, however, is the risk of immunizing women
in unrecognized early pregnancy or women who may
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become pregnant immediately after vaccination. In
such situations, it has been shown that in susceptible
women the attenuated virus can produce chronic
placental infection which may be transmitted to
the fetus. Generally, when vaccinations have been
performed early in gestation, therapeutic abortion
has been performed. Too few pregnancies have
proceeded to term to determine the possible consequences of fetal infection with vaccine virus. Thus
it is highly important when vaccinating adult women, to insure that the patient is not pregnant
and will not become pregnant for at least two
months after immunization. Pretesting of women
for HAI antibodies is recommended and will exclude the necessity for using vaccine in immune
women.
If vaccines are used extensively and if the
immune status of the population can be maintained at a high level, it seems possible that rubella
control can be achieved.
In comparison with the abundance of information available about rubella, knowledge of the
epidemiology and pathogenesis of congenital CMV
infections is limited. Thirty to sixty percent of
childbearing age women have detectable antibodies. Infection during the reproductive years
may be quite common. Serologic responses occurred
in 3 % to 5 % of pregnant women in two urban
centers studied. Information is not currently available concerning the frequency with which maternal
infection is transmitted to the fetus. It is also
unclear what proportion of fetal infections are
( 1) inapparent, (2) silent at birth but produce
clinical manifestations later, or (3) result in classical
cytomegalic inclusion disease. The reason for this
poor documentation is in part attributable to the
fact that maternal infections are subclinical. Rarely
acute CMV infection in the adult may mimiC infectious mononucleosis. Diagnosis of maternal CMV
infection by virus recovery is hampered by the
observation that virus may be shed in the urine
for periods up to 2 years following initial infection;
thus recovery of virus from a pregnant woman does
not necessarily indicate acute disease.
The occurrence of the majority of congenital
CMV infection in babies born to young primiparous
mothers, suggests that intrauterine infection is most
commonly acquired by the fetus during the viremic
phase of primary maternal CMV infection. Fetal
infection may occur in the first trimester (Davis,
et al, 1971) and perhaps later in pregnancy as well.
As in rubella, it has been shown that placental infection may occur without infection of the fetus .
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Congenital CMV infection in 2 siblings born
within 8 months of one another has been recently
reported (Emil, et al, 1970). The possibility of
such an occurrence should not be overlooked in
the follow-up of women who have borne a CMV
affected child.
Adding to the complexity of the CMV problem is the observation that multiple antigenic variants of the virus exist; the significance of this variation in the virus for immunity and the possibility of
reinfection is unknown.
The features of classical congenital cytomegalic
inclusion disease include, like rubella, defects in
CNS, eye, and hepatic and bone marrow function. Microcephaly and hydrocephaly, encephalitis,
cerebral calcifications, convulsive disorders, chorioretinitis, blindness, hepatosplenomegaly with jaundice, thrombocytopenia with petechiae, anemia,
and interstitial pneumonia all can occur. Unlike
the rubella syndrome, cataracts and heart defects
are not seen.
As in congenital rubella, virus can be recovered from throat, urine, and blood of affected
live born children and from multiple tissues of
aborted or stillborn fetuses. Virus recovery from
clinical specimens, unless accomplished in the immediate newborn period, cannot be taken as certain
indication of an etiologic relationship between
defects and CMV infection since these viruses can
be recovered with some frequency from urine of
asymptomatic children. The demonstration of elevated serum IgM and the persistent occurrence
of specific CMV IgM antibodies in the serum of
newborn infants provides convincing evidence of
intrauterine infection (Sever and White, 1968;
Alford, et al, 1967).
Aside from the experimental use of chemotherapeutic agents which inhibit replication of DNA
viruses in children with the congenital disease, no
methods of prevention or treatment are currently
available.
What new developments are likely to occur
which might be important from the standpoint
of congenital infections? Several recent reviews
have explored the status of other viral agents in
producing abortions, stillbirths, and neonatal disease. It has been speculated on the basis of
epidemiologic studies that other agents including
varicella, vaccinia, mumps, influenza, and measles
viruses may possibly induce fetal defects (Sever
and White, 1968; Hardy, 1965). The etiologic relationship of these viruses with congenital defects
are not in hand, but with additional study might

yet be proven. Perhaps other mechanisms than
those active in rubella and CMV infections will
be shown important. An even more interesting
possibility relates to the cancer virus field. Impressive evidence is available indicating that many
tumors of amphibians, birds, rodents, and cats are
caused by viruses. The study of animal model sys··
terns in chickens and mice indicates that RNA
leukemia viruses may be transmitted "vertically,"
that is, directly from mother to embryo. The incidence of malignant disease in the congenitally infected animal is higher than that seen in the adult
host infected by contact. Could such situations
exist in man? Enough parallels exist between the
human and animal diseases to make this a tantalizing possibility. Perhaps as techniques for searching out human oncogenic viruses become more
sophisticated, similar agents may one day be recognized as causing highly important congenitally
acquired infections.
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